OPEN END TURBO LONG - ROCHE GS Share Price

Certificat

DE000MA4EB74

Market Closed - Börse Stuttgart 09:53:36 14/06/2024 pm IST
4.5 EUR +4.90% Intraday chart for OPEN END TURBO LONG - ROCHE GS
Current month+70.45%
1 month+120.59%
Date Price Change
14/24/14 4.5 +4.90%
13/24/13 4.29 +4.63%
12/24/12 4.1 +6.77%
11/24/11 3.84 +6.37%
10/24/10 3.61 -7.20%

Delayed Quote Börse Stuttgart

Last update June 14, 2024 at 09:53 pm IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Morgan Stanley
WKN MA4EB7
ISINDE000MA4EB74
Date issued 29/12/2020
Strike 205.1 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 9.7
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 20.28
Lowest since issue 1.04

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus